TickerFacts.

Liminatus Pharma, Inc. (LIMN): EPS (Diluted)

Annual figures by period end, from SEC filings.

-$0.43
Year ended 2025-12-31
2024-12-31: -$0.202025-12-31: -$0.43-$0.43
2024-12-31 EPS (Diluted) (USD per share) 2025-12-31
Period endedEPS (Diluted)Change YoYSource filing
2025-12-31-$0.43n/m2026-03-31, From 2025-01-01
2024-12-31-$0.20n/a2026-03-31, From 2024-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Diluted)Change YoY
Liminatus Pharma, Inc. (LIMN)2025-12-31-$0.43n/m
Adaptin Bio, Inc. (APTN)2025-12-31-$0.66n/m
Brainstorm Cell Therapeutics Inc. (BCLI)2025-12-31-$1.11n/m
Abpro Holdings, Inc. (ABPO)2025-12-31-$1.30n/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$0.86n/m
Zivo Bioscience, Inc. (ZIVO)2024-12-31-$4.23n/m
Estrella Immunopharma, Inc. (ESLA)2025-12-31-$0.35n/a
Tevogen Inc. (TVGN)2025-12-31-$8.08n/m
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31-$0.49n/m

Compare LIMN, APTN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗